- Home
- CHRS vs KVHI Comparison
CHRS vs KVHI Comparison
Compare CHRS & KVHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- KVHI
- Stock Information
- Founded
- CHRS 2010
- KVHI 1978
- Country
- CHRS United States
- KVHI United States
- Employees
- CHRS N/A
- KVHI N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- KVHI Radio And Television Broadcasting And Communications Equipment
- Sector
- CHRS Health Care
- KVHI Technology
- Exchange
- CHRS Nasdaq
- KVHI Nasdaq
- Market Cap
- CHRS 112.5M
- KVHI 100.2M
- IPO Year
- CHRS 2014
- KVHI 1996
- Fundamental
- Price
- CHRS $0.76
- KVHI $5.19
- Analyst Decision
- CHRS Strong Buy
- KVHI
- Analyst Count
- CHRS 4
- KVHI 0
- Target Price
- CHRS $5.26
- KVHI N/A
- AVG Volume (30 Days)
- CHRS 1.7M
- KVHI 22.3K
- Earning Date
- CHRS 05-12-2025
- KVHI 05-07-2025
- Dividend Yield
- CHRS N/A
- KVHI N/A
- EPS Growth
- CHRS N/A
- KVHI N/A
- EPS
- CHRS N/A
- KVHI N/A
- Revenue
- CHRS $272,251,000.00
- KVHI $109,975,000.00
- Revenue This Year
- CHRS N/A
- KVHI $4.22
- Revenue Next Year
- CHRS N/A
- KVHI $13.27
- P/E Ratio
- CHRS N/A
- KVHI N/A
- Revenue Growth
- CHRS 19.87
- KVHI N/A
- 52 Week Low
- CHRS $0.66
- KVHI $4.17
- 52 Week High
- CHRS $2.43
- KVHI $6.16
- Technical
- Relative Strength Index (RSI)
- CHRS 36.67
- KVHI 55.59
- Support Level
- CHRS $0.71
- KVHI $4.95
- Resistance Level
- CHRS $1.06
- KVHI $5.41
- Average True Range (ATR)
- CHRS 0.08
- KVHI 0.20
- MACD
- CHRS -0.03
- KVHI 0.03
- Stochastic Oscillator
- CHRS 12.44
- KVHI 52.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About KVHI KVH Industries Inc.
KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.